Guanfacine Extended-release Tablet, Extended Release
Product Images NDC 71335-3005

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Guanfacine Extended-release (NDC 71335-3005). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph comparing guanfacine plasma concentration (ng/mL) over 24 hours between extended-release guanfacine 1 mg once daily and immediate-release guanfacine 1 mg once daily. The graph shows plasma levels on the y-axis and time in hours on the x-axis, illustrating pharmacokinetic profiles for both formulations.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A figure showing fold changes and 90% confidence intervals in pharmacokinetic parameters (Cmax and AUC) for Guanfacine extended-release when coadministered with various CYP3A4/5 inhibitors and inducers, and other drugs like oral methylphenidate and lisdexamfetamine dimesylate. The horizontal axis plots change relative to reference values.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A chart depicting the pharmacokinetic effects of interacting drugs oral methylphenidate and lisdexamfetamine dimesylate on Cmax and AUC. It shows fold change and 90% confidence intervals relative to a reference, with values plotted along a horizontal axis from 0.0 to 2.0.*
FDA Label Image

Figure4.jpg (Figure4)

Figure4.jpg (Figure4)
A line graph depicting treatment failure percentage over time in days. It compares placebo with SPD503, showing treatment failure increasing over approximately 200 days. The x-axis is labeled 'Time to Treatment Failure (Days)' and the y-axis is labeled 'Treatment Failure (%)'. Placebo is represented by a solid line, SPD503 by a dashed line, illustrating lower failure rates with SPD503.*
FDA Label Image

Label (Lbl713353005)

Label (Lbl713353005)
Label for Guanfacine extended-release tablets, USP, 4 mg strength. The label shows the NDC number 71335-3005-1 and indicates the package contains 100 tablets. The product is labeled by Bryant Ranch Prepack and manufactured by Apotex Inc. Storage and handling instructions are provided, along with QR codes for package insert information.*
FDA Label Image

Spd503-chemical-stucture (Spd503 Chemical Stucture)

Spd503-chemical-stucture (Spd503 Chemical Stucture)
Chemical structure of guanfacine hydrochloride is shown, illustrating its molecular configuration including chlorine atoms and the hydrochloride component as indicated by HCl.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.